The Therapeutic Goods Administration has approved Telix Pharmaceuticals’ prostate cancer imaging product – its first regulatory approval, helping to push its market capitalisation beyond $2 billion.
The biotech’s shares raced ahead on Tuesday jumping 54¢, or 8.13 per cent, to $7.18 each – gaining back some recent losses but still shy of the high it hit in September of $7.46.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
